DIGITAL BIO PHARM LTD

COMPANY PRESENTATION
2014
Web-site: www.digitalbiopharm.com
E-mail: contact@digitalbiopharm.com
Tel: +47 46 22 77 96
Correspondence:
145-157 Street, St. John Street , London
EC1V 4PW, United Kingdom
AGENDA
1
2
3
Philosophy of the company
Business model
Services
Web-site: www.digitalbiopharm.com
E-mail: contact@digitalbiopharm.com
Tel: +47 46 22 77 96
Correspondence:
145-157 Street, St. John Street , London
EC1V 4PW, United Kingdom
Philosophy of the company
DigitalBioPharm is an early-stage drug discovery company with a bias
toward computer-based drug design methods.
1
Our goal is to get our expertise involved
in the most interesting and innovative
projects in the most promising fields of
drug discovery. Our long-term goal is the
reduction of costs and time for
preclinical drug development through
the reduction of the amount of wet-lab
work and its replacement by
corresponding computational
simulations.
Web-site: www.digitalbiopharm.com
E-mail: contact@digitalbiopharm.com
Tel: +47 46 22 77 96
Correspondence:
145-157 Street, St. John Street , London
EC1V 4PW, United Kingdom
Business model
Collaboration through scientific research, with IP shared
Services on milestone basis, including providing services in collaboration
with other companies
2
Sale of consulting hours in a specified field
Internal research projects with separate
investments and IP sales for each project
Internal research projects funded by public
funding sources through scientific
collaboration
Web-site: www.digitalbiopharm.com
E-mail: contact@digitalbiopharm.com
Tel: +47 46 22 77 96
Correspondence:
145-157 Street, St. John Street , London
EC1V 4PW, United Kingdom
Services
Structure-based drug design
Ligand-based drug design
Molecular modeling
Medicinal and organic chemistry
ADME/Tox optimization
Management of complex drug
discovery projects
3
Web-site: www.digitalbiopharm.com
E-mail: contact@digitalbiopharm.com
Tel: +47 46 22 77 96
Correspondence:
145-157 Street, St. John Street , London
EC1V 4PW, United Kingdom
Structure-based drug design services:
Binding site identification and evaluation of target protein druggability
Docking and virtual screening
Fragment-based drug design
Pharmacophore models, pharmacophore-based
screening
Protein-ligand interactions studies, affinity
and free binding energy evaluation
Selectivity profiling of compounds against several proteins
QM-MM methods for protein - ligand interactions
Free energy simulations for improved binding affinity models
Molecular dynamics analysis of protein conformations and protein-ligand
interactions
Web-site: www.digitalbiopharm.com
E-mail: contact@digitalbiopharm.com
Tel: +47 46 22 77 96
Correspondence:
145-157 Street, St. John Street , London
EC1V 4PW, United Kingdom
Ligand-based drug design
Focused library design for lead generation and optimization
Designing and filtering virtual libraries on the
basis of similarity, potency or ADME/Tox properties
Chemoinformatics and QSAR, including 3D QSAR
Similarity-Diversity analysis
Conformational analysis, 3D structures
generation and databases preparation
Web-site: www.digitalbiopharm.com
E-mail: contact@digitalbiopharm.com
Tel: +47 46 22 77 96
Correspondence:
145-157 Street, St. John Street , London
EC1V 4PW, United Kingdom
Molecular modeling
Homology modeling and protein structures
preparation
Binding site identification and analysis
Proteins comparative structural analysis for
selectivity design to homologous target and
anti-target proteins
Structure visualization, 3D representation and
depiction
Molecular dynamics studies, conformational
analysis of proteins and protein-ligand
interactions
Conformational analysis of peptides and small
molecules
Web-site: www.digitalbiopharm.com
E-mail: contact@digitalbiopharm.com
Tel: +47 46 22 77 96
Correspondence:
145-157 Street, St. John Street , London
EC1V 4PW, United Kingdom
ADME/Tox optimization
Permeability optimization according the MDCK, Caco-2
and corneal permeability models
Metabolism analysis, substrate reactivity prediction
and sites of metabolism (SoM) identification,
metabolites prediction. CYP stability evaluation and
optimization.
General and specific toxicity optimization
Solubility evaluation and optimization
Evaluation and optimization of key drug-like properties
Drug-like and lead-like databases processing and design
Blood-brain barrier penetration optimization
Web-site: www.digitalbiopharm.com
E-mail: contact@digitalbiopharm.com
Tel: +47 46 22 77 96
Correspondence:
145-157 Street, St. John Street , London
EC1V 4PW, United Kingdom
Medicinal and organic chemistry
Lead optimization, such as reduction of
side-effects, enhancing bioactivity and
bioavailability, improving solubility.
Backup leads development
Retrospective synthesis analysis
Design of organic synthesis routes
Organic synthesis costs evaluation and
CRO selection
Synthetic route scouting
Target-focused library building
Patents breaking, patents exemplification
Web-site: www.digitalbiopharm.com
E-mail: contact@digitalbiopharm.com
Tel: +47 46 22 77 96
Correspondence:
145-157 Street, St. John Street , London
EC1V 4PW, United Kingdom
Management of complex drug
Project planning and disease selection (including orphan)
Investments and grants funding proposal preparations
Biotargets prioritization, selection and validation
Hit-to-lead and lead optimization services
Preclinical trials organization
Patents preparation and exemplification
drug development projects
www.digitalbiopharm.com
E-mail: contact@digitalbiopharm.com
Tel: +47 46 22 77 96

Correspondence: 145-157 Street, St. John Street , London
EC1V 4PW , United Kingdom
Contact